<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03752996</url>
  </required_header>
  <id_info>
    <org_study_id>2011-03</org_study_id>
    <nct_id>NCT03752996</nct_id>
  </id_info>
  <brief_title>ACURATE TF™ Transfemoral Aortic Bioprosthesis for Implantation in Patients With Severe Aortic Stenosis (2011-03)</brief_title>
  <acronym>2011-03</acronym>
  <official_title>ACURATE TF™ Transfemoral Aortic Bioprosthesis for Implantation in Patients With Severe Aortic Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Symetis SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      First-In-Man Study on the ACURATE TF™ Transfemoral Aortic Bioprosthesis Implantation in
      Patients with Severe Aortic Stenosis to collect human feasibility data pertaining to the
      safety and performance of the device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single arm, prospective, multicenter, non-randomized, open trial, up to 5 Years follow-up
      with the Symetis ACURATE TF™ Transfemoral Aortic Bioprosthesis for minimal invasive
      implantation via transfemoral access to treat patients with severe aortic stenosis where
      conventional aortic valve replacement (AVR) via open heart surgery is considered to be
      associated with high risk.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 9, 2012</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Actual">June 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from all-cause mortality</measure>
    <time_frame>30-Days</time_frame>
    <description>Rate of all-cause mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of MACCE (major cardiac and cerebrovascular event)</measure>
    <time_frame>30-Days and 12-Months</time_frame>
    <description>Rate of major cardiac and cerebrovascular event (MACCE) defined as cardiovascular death, myocardial infarction and stroke</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Aortic Stenosis Symptomatic</condition>
  <arm_group>
    <arm_group_label>ACURATE TF™ Aortic Valve System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACURATE TF™ Aortic Valve System is intended for subjects with severe symptomatic Aortic Stenosis and considered high risk for surgical conventional Aortic Valve Replacement .</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ACURATE TF™ Aortic Valve System</intervention_name>
    <description>Transcatheter Aortic Valve Implantation</description>
    <arm_group_label>ACURATE TF™ Aortic Valve System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients 75 years of age and older

          2. Logistic EuroSCORE ≥ 20%

          3. Severe aortic stenosis characterized by mean aortic gradient &gt; 40 mmHg or peak jet
             velocity &gt; 4.0 m/s or aortic valve area &lt; 1.0 cm2

          4. New York Heart Association (NYHA) Functional Class &gt; II

          5. Aortic annulus diameter from ≥ 21mm up to ≤ 27mm measured by TEE

          6. Patient not a surgical candidate due to significant co-morbid conditions unrelated to
             aortic stenosis

          7. Patient willing to participate in the study and provide signed informed consent

        Exclusion Criteria:

          1. Unicuspid or bicuspid aortic valve

          2. Extreme eccentricity of calcification

          3. Severe mitral regurgitation ( &gt;2+)

          4. Pre-existing prosthetic heart valve in any position and / or prosthetic ring

          5. Aortic or peripheral anatomy NOT appropriate for transfemoral implant

          6. Thoracic (TAA) or abdominal (AAA) aortic aneurysm

          7. Presence of endovascular stent graft for treatment of TAA or AAA

          8. Trans-esophageal echocardiogram (TEE) is contraindicated

          9. Left Ventricle Ejection Fraction (LVEF) &lt; 30% by echocardiography (ECHO)

         10. ECHO evidence of intracardiac mass, thrombus, or vegetation

         11. Acute Myocardial Infarction (AMI) within 1 month prior to implant procedure

         12. Percutaneous Coronary Intervention (PCI), except for balloon valvuloplasty (BAV)
             within 1 month prior to implant procedure

         13. Previous Transient Ischemic Attack (TIA) or stroke within 3 months prior to implant
             procedure

         14. Active ulcer or gastrointestinal (GI) bleeding within 3 months prior to implant
             procedure

         15. Any scheduled surgical or percutaneous procedure to be performed prior to 30 day visit

         16. History of bleeding diathesis or coagulopathy or refusal of blood transfusions

         17. Systolic pressure &lt;80 mmHg, cardiogenic shock, need for inotropic support or
             Intra-Aortic Balloon Pump (IABP)

         18. Primary hypertrophic obstructive cardiomyopathy (HOCM)

         19. Active infection, endocarditis or pyrexia

         20. Hepatic failure

         21. Chronic renal dysfunction with serum creatinine &gt; 2.5 mg/dL or renal dialysis

         22. Refusal of surgery

         23. Severe Chronic Obstruction Pulmonary Disease (COPD) requiring home oxygen

         24. Neurological disease severely affecting ambulation or daily functioning, or dementia

         25. Life expectancy &lt; 12 months due to non-cardiac co-morbid conditions

         26. Known hypersensitivity/contraindication to study medication, contrast media, or
             nitinol

         27. Currently participating in an investigational drug or another device study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese de Cardiologia</name>
      <address>
        <city>Sao Paulo</city>
        <zip>CEP 04012-909</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff Klinik GmbH</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäres Herzzentrum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Universitätsklinikum Köln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 21, 2018</study_first_submitted>
  <study_first_submitted_qc>November 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2018</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

